A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The role of U300 glargine insulin for the inpatient management of type 2 diabetes (T2D) has not been determined. We compared the safety and efficacy of glargine U300 versus glargine U100 in noncritically ill patients with T2D. RESEARCH DESIGN AND METHODS: This prospective, open-label, randomized clinical trial included 176 patients with poorly controlled T2D (admission blood glucose [BG] 228 ± 82 mg/dL and HbA1c 9.5 ± 2.2%), treated with oral agents or insulin before admission. Patients were treated with a basal-bolus regimen with glargine U300 (n = 92) or glargine U100 (n = 84) and glulisine before meals. We adjusted insulin daily to a target BG of 70–180 mg/dL. The primary end point was noninferiority in the mean difference in daily BG between groups. The major safety outcome was the occurrence of hypoglycemia. RESULTS: There were no differences between glargine U300 and U100 in mean daily BG (186 ± 40 vs. 184 ± 46 mg/dL, P = 0.62), percentage of readings within target BG of 70–180 mg/dL (50 ± 27% vs. 55 ± 29%, P = 0.3), length of stay (median [IQR] 6.0 [4.0, 8.0] vs. 4.0 [3.0, 7.0] days, P = 0.06), hospital complications (6.5% vs. 11%, P = 0.42), or insulin total daily dose (0.43 ± 0.21 vs. 0.42 ± 0.20 units/kg/day, P = 0.74). There were no differences in the proportion of patients with BG <70 mg/dL (8.7% vs. 9.5%, P > 0.99), but glargine U300 resulted in significantly lower rates of clinically significant hypoglycemia (<54 mg/dL) compared with glargine U100 (0% vs. 6.0%, P = 0.023). CONCLUSIONS: Hospital treatment with glargine U300 resulted in similar glycemic control compared with glargine U100 and may be associated with a lower incidence of clinically significant hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RCTs have shown that treatment with a basal prandial regimen using insulin analogs improved glycemic control with fewer hospital complications in general medical and surgical persons with T2D compared with sliding-scale regular insulin alone.92,107,108,1333–1336”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1335]
In the citing paper
“Data on the use of concentrated insulins such as glargine U-300, degludec U-200, and U-500 regular insulin in the inpatient and perioperative settings are limited and have shown variable results (78-81).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [79]
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“In addition, glucose values obtained with CGMwere analyzed to compare the percentage of time that the sensor glucose measurement was below the target range (54–69mg/dL and,54mg/dL) (23).”
MethodStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Self-citationMalmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Van den Berghe, G., Wouters, P. J., Bouillon, R., Weekers, F., Verwaest, C., Schetz, M., Vlasselaers, D., Ferdinande, P., & Lauwers, P. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045568.12881.10 · Cited by 1,455
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Self-citationUmpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Self-citationGlucose Control and Mortality in Critically Ill Patients
Finney, S. J. (2003) · JAMA · doi:10.1001/jama.290.15.2041 · Cited by 1,055
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720 · cited 6×
“The results of multiple clinical trials in the hospital setting suggest that patients with diabetes may respond differently to a commonly used basal-bolus approach (7,9,12,24,25,29).”
BackgroundMethodResultInfluentialSelf-citationEarly Postoperative Glucose Control Predicts Nosocomial Infection Rate in Diabetic Patients
Pomposelli, J. J., Baxter, J. K., Babineau, T. J., Pomfret, E. A., Driscoll, D. F., Forse, R. A., & Bistrian, B. R. (1998) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860719802200277 · Cited by 700
Umpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R. (2007) · Diabetes Care · doi:10.2337/dc07-0295 · Cited by 671
Self-citationInternational Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
The International Hypoglycaemia Study Group (2017) · Diabetologia · doi:10.1007/s00125-016-4146-6 · Cited by 360
Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Umpierrez, G. E., Smiley, D., Hermayer, K., Khan, A., Olson, D. E., Newton, C., Jacobs, S., Rizzo, M., Peng, L., Reyes, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1988 · Cited by 222
Self-citationHome, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Galindo, R. J., Migdal, A. L., Davis, G. M., Urrutia, M. A., Albury, B., Zambrano, C., Vellanki, P., Pasquel, F. J., Fayfman, M., Peng, L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2073 · Cited by 181
Self-citationUmpierrez, G. E., Hor, T., Smiley, D., Temponi, A., Umpierrez, D., Ceron, M., Munoz, C., Newton, C., Peng, L., & Baldwin, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1441 · Cited by 179 · cited 3×
“Despite improvement in glycemic control, up to 30% of patients in clinical trials developed hypoglycemia in the hospital, depending on their clinical characteristics (7,9,12).”
BackgroundSelf-citationPasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168 · cited 3×
“These values are lower than in previous RCTs (9,12,24,25).”
BackgroundResultSelf-citationSliding Scale Insulin Use: Myth or Insanity?
Umpierrez, G. E., Palacio, A., & Smiley, D. D. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.070 · Cited by 155
Self-citationYki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., & Riddle, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12532 · Cited by 131
Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis
Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0169 · Cited by 120 · cited 3×
“Procedures Patients were treated with a basal-bolus insulin regimen approach as previously reported (see Supplementary Data) (9,12,21).”
MethodInfluentialSelf-citationRiddle, M. C., Yki‐Järvinen, H., Bolli, G. B., Ziemen, M., Muehlen‐Bartmer, I., Cissokho, S., & Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12472 · Cited by 110
Fayfman, M., Galindo, R. J., Rubin, D. J., Mize, D. L., Anzola, I., Urrutia, M. A., Ramos, C., Pasquel, F. J., Haw, J. S., Vellanki, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1760 · Cited by 85 · cited 1×
“Recent pilot data suggest that the combination of a GLP-1 RA with basal insulin may be effective in the hospital but associated with an expected increase in gastrointestinal adverse effects (32).”
BackgroundSelf-citationVellanki, P., Rasouli, N., Baldwin, D., Alexanian, S., Anzola, I., Urrutia, M., Cardona, S., Peng, L., Pasquel, F. J., Umpierrez, G. E., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13587 · Cited by 80
Self-citationPasquel, F. J., Fayfman, M., & Umpierrez, G. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1184-8 · Cited by 60 · cited 3×
“We enrolled adult patients (.18 years of age) with a known history of T2D treated with diet alone, any combination of oral antidiabetes agents, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) (except long-acting GLP-1 RAs), or insulin therapy (except degludec or glargine U300) admitted to a general medicine or s…”
BackgroundInfluentialSelf-citationPasquel, F. J., Gomez-Huelgas, R., Anzola, I., Oyedokun, F., Haw, J. S., Vellanki, P., Peng, L., & Umpierrez, G. E. (2015) · Diabetes Care · doi:10.2337/dc15-1835 · Cited by 55 · cited 2×
“The results of multiple clinical trials in the hospital setting suggest that patients with diabetes may respond differently to a commonly used basal-bolus approach (7,9,12,24,25,29).”
BackgroundSelf-citationNew Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J. D., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Yale, J., Berard, L., Groleau, M., Javadi, P., Stewart, J. A., & Harris, S. B. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.007 · Cited by 32 · cited 1×
“A much more conservative patient-driven titration algorithm of 1 unit/day of glargine U300 may be safer and effective in a primary care setting (33).”
BackgroundEscalada, J., Halimi, S., Senior, P. A., Bonnemaire, M., Cali, A. M. G., Melas‐Melt, L., Karalliedde, J. J., & Ritzel, R. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13470 · Cited by 23
Philis‐Tsimikas, A., STRATTON, I. M., Troelsen, L. N., Bak, B. A., & Leiter, L. A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819841585 · Cited by 22 · cited 1×
“glargine U300) have been reported in the inpatient setting (28).”
BackgroundInsulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus
Clements, J. N., & Bello, L. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150174 · Cited by 17
Monnier, L., Owens, D. R., & Bolli, G. B. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.11.005 · Cited by 14
Suzuki, J., Yamakawa, T., Oba, M. S., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0309 · Cited by 13 · cited 1×
“Of interest, a recent smaller RCT (n 5 74) examined the efficacy of the other available longacting insulin degludec compared with glargine U100 in patients with T2D admitted for glycemic control optimization (27).”
BackgroundGalindo, R. J., Urrutia, M. A., Davis, G. M., Khowaja, A. A., Albury, B. S., Anzola, I., JOHNSON, A. A., Vellanki, P., Cardona, S., Fayfman, M., et al. (2019) · Diabetes · doi:10.2337/db19-908-p · Cited by 1
Self-citation
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationManagement of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s016 · Cited by 195
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Galindo, R. J., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s016 · Cited by 167
Self-citationGalindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932903 · Cited by 155
Self-citation
Metadata
- Authors
- Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., Vellanki, P., Peng, L., & Umpierrez, G. E.
- Affiliations
- Emory University (US)
- Cleveland Clinic (US)
- University of Minnesota (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-09
- Volume
- 43
- Issue
- 6
- Pages
- 1242-1248
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7411278
- OpenAlex
- W3015651592
- Cited by
- 45
- References
- 37
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 12 · 2021: 5 · 2020: 6
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- long-acting insulin, inpatient diabetes management, multiple daily insulin injections, glulisine, hypoglycemia, glycemic control, non-inferiority, length of hospital stay, in-hospital complications, insulin dose reduction, non-critically ill patients, uncontrolled diabetes
- MeSH terms
- Insulin Glargine, Equivalence Trials as Topic, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Inpatients, Internal Medicine, Male, Middle Aged, Minnesota, Surgery Department, Hospital
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.